Analyst Joseph Schwartz works at LEERINK and is focused on the Healthcare sector with 592 price targets and ratings documented since 2008 spanning on 37 stocks. Analyst's average stock valuation to be materialised ratio is 52.93% with an average time for price targets to be met of 253.86 days.
Most recent stock forecast was given on BMRN, BioMarin Pharmaceutical Inc at 03-Feb-2023.
Joseph Schwartz best performing recommendations are on RETA (REATA PHARMACEUTICALS, INC).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS, INC) at 10/14/2019. The price target of $180 was fulfilled within 4 days with a profit of $79.41 (78.94%) receiving and performance score of 197.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
14
2 years 4 months 1 days ago
12/17 (70.59%)
$0.4 (2.24%)
60
Hold
10
$-3.75 (-27.27%)
7
2 years 5 months 18 days ago
7/11 (63.64%)
$5.63 (20.89%)
138
Hold
10
$-3.75 (-27.27%)
14
2 years 5 months 19 days ago
1/4 (25%)
$5.83 (60.02%)
6
Hold
10
$-3.75 (-27.27%)
2 years 5 months 30 days ago
3/5 (60%)
$10.1 (29.35%)
211
Hold
13
$-0.75 (-5.45%)
19
3 years 8 months 30 days ago
4/5 (80%)
$4.63 (17.01%)
198
